Kyverna Therapeutics, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The Complaint claims that the Defendants made materially false and/or misleading statements and failed to disclose significant negative information about the Company’s business, operations, and prospects. Specifically, the Complaint asserts that Kyverna was aware of critical, undisclosed data related to one of its clinical trials that could adversely affect its lead product. The Complaint further contends that these undisclosed negative findings had a substantial impact on the company’s prospects, rendering the results and trends presented in the Registration Statement and Prospectus for the Initial Public Offering misleading and not reflective of Kyverna’s future performance.
Additionally, the Complaint alleges that once the truth came to light after the Offering, the Company’s stock price dropped significantly. By the time this action was filed, Kyverna’s shares had fallen to as low as $3.92 per share, a decline of more than 82% from the $22 IPO Offering Price.
